GoodRx Holdings

GDRX

Market cap $1.33B

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription for hair loss treatment. Built for simplicity and transparency, GoodRx for Hair Loss helps men access affordable treatments that are clinically proven to slow hair loss and support regrowth. Hair loss is one of the most common health concerns among men. By age 50, about half of all men in the U.S. experience some degree of thinni.

GoodRx is leveraging partnerships with Novo Nordisk and potential TrumpRx involvement to offset stagnating user growth and drive higher-margin revenue. Despite a 14% decline in Monthly Active Consumers, GDRX improved average revenue per user and maintains high gross margins above 90%. Valuation appears modestly undervalued, with scenario analysis showing upside if collaborations materialize, but competition and shrinking user base remain concerns.

Prescription savings platform GoodRx Holdings Inc. (NASDAQ:GDRX) is reportedly joining the so-called TrumpRx website, signaling an initiative expansion beyond pharmaceutical manufacturers' direct discount programs.

Retail pharmacies and prescription drug savings site GoodRx are talking with the Trump administration about joining its TrumpRx website, they told Reuters, suggesting an expansion beyond the early description of it as a link to pharmaceutical companies' direct discounts.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's bus.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price. “In a healthcare system where affordability too often dictates access, GoodRx re.

Prescription platform GoodRx has launched a brand medication savings solution with supermarket chain Kroger. RxSmartSave, announced Wednesday (Oct. 1), is now available at Kroger pharmacies in 35 states around the country, GoodRx said in a news release.

GoodRx said on Wednesday it has partnered with Kroger's healthcare unit to expand its prescription savings services for branded drugs, including Novo Nordisk's popular weight-loss drug Wegovy.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of its brand medication savings solution, RxSmartSaver powered by GoodRx, at Kroger pharmacies nationwide. RxSmartSaver brings medication affordability directly to the pharmacy counter, improving the patient experience while delivering stronger economics for the retail partner. “Friction at the pharmacy counter causes frustration for both pharma.

GoodRx offers compelling value after a ~50% stock decline over the past 12 months, trading at just 6.1x FY25 adjusted EBITDA despite recent execution challenges. A new Novo Nordisk partnership for Ozempic and Wegovy discounts could attract new users and offset recent guidance cuts and Rite Aid-related headwinds. The company cut its revenue and adjusted EBITDA outlook for FY25, which was widely expected after the bankruptcy of Rite Aid.